生命第一年接种疫苗与特应性疾病风险——KiGGS研究结果
基于德国儿童青少年健康访谈与检查调查(KiGGS,2003-2006)数据,分析生命第一年疫苗接种与第一年后特应性疾病诊断风险的关系。分析花粉症、特应性皮炎或哮喘的样本量分别为15254、14297和15262。生命第一年末TDPHiHeP疫苗接种充足的儿童,第一年后诊断花粉症的风险较低(调整患病率比0.85,95%CI 0.76-0.96)。未发现免疫接种增加特应性疾病风险的证据。
要点
- 生命第一年末TDPHiHeP疫苗接种充足与第一年后花粉症诊断风险较低相关(调整患病率比0.85,95%CI 0.76-0.96)。
- TDPHiHeP疫苗接种与特应性皮炎或哮喘风险、疫苗接种起始年龄或第一年接种抗原数量与特应性疾病风险的分析均未达统计学显著。
- 结果无证据表明生命第一年免疫接种可能增加特应性疾病风险。
核心结论
- 结果无证据表明生命第一年免疫接种可能增加特应性疾病风险。
- 若存在任何关联,结果可被解释为弱支持免疫接种可能轻度降低晚年特应性风险的假说。
研究设计与样本
- 分析德国儿童青少年健康访谈与检查调查(KiGGS,2003-2006)数据。
- 分析花粉症、特应性皮炎或哮喘风险的样本量分别为15254、14297和15262。
主要发现
- 生命第一年末TDPHiHeP疫苗接种充足的儿童,第一年后诊断花粉症的风险较低(调整患病率比0.85,95%CI 0.76-0.96)。
- TDPHiHeP疫苗接种与特应性皮炎或哮喘风险的分析未达统计学显著。
- 疫苗接种起始年龄或第一年接种抗原数量与特应性疾病风险的分析未达统计学显著。
关键数值与推荐
- 生命第一年末TDPHiHeP疫苗接种充足者第一年后花粉症诊断的调整患病率比为0.85(95%CI 0.76-0.96)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The study focused on the question of whether and - if so - to what direction and extent immunisations in the 1st year may be associated with the risk of being diagnosed with atopic diseases after the 1st year of life. METHODS: Data from the German Health Interview and Examination Survey for Children and Adolescents (KiGGS, 2003-2006) were analysed. For analyses of potential associations between vaccination status and risk of hay fever, atopic dermatitis or asthma, sample sizes of 15254, 14297, and 15262, respectively, were available. RESULTS: Children with a sufficient TDPHiHeP vaccination at the end of the 1st year of life had a lower risk of being diagnosed with hay fever after the 1st year of life (adjusted prevalence ratio 0.85, 95% confidence interval 0.76-0.96). Analyses for associations between TDPHiHeP vaccination and risk of atopic dermatitis or asthma, or between age at onset of vaccination or of the number of antigens vaccinated in the 1st year of life and risk of atopic disease failed to yield statistical significance. CONCLUSIONS: Our results provide no evidence that immunisations in the 1st year of life may increase the risk of atopic disease. If any association exists at all, our results may be interpreted as weakly supportive of the hypothesis that immunisations may slightly decrease the risk of atopy in later life.
引用
- Schlaud M, Schmitz R, Poethko-Müller C, et al. Vaccinations in the first year of life and risk of atopic disease - Results from the KiGGS study. Vaccine. 2017. PMID: 28801155. doi:10.1016/j.vaccine.2017.07.111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。